The Relevance of AI in Mastering Polypharmacy Management

By Danélia Botes

April 29, 2024


The demographic landscape is undergoing a significant transformation. By 2050, the segment of the population aged over 60 is set to double, as per the World Health Organization. This demographic shift presents a growing challenge to healthcare systems worldwide, particularly in the management of polypharmacy, defined as the concurrent use of five or more medications. Over 40% of older adults are now navigating the complexities of polypharmacy, often under the guidance of their primary care physicians (PCPs).

The Challenge of Polypharmacy

PCPs are witnessing an increased burden, with a 34% rise in specialist consultations for Medicare beneficiaries since 2000. The intricate web of medications prescribed by various specialists often culminates in the hands of PCPs, who must manage potential drug interactions and adverse effects. Deprescribing, the process of reducing or stopping medications that may no longer be beneficial or might be harmful, is a crucial but intricate strategy in mitigating these risks.

AI-Assisted Deprescribing: A New Frontier

Recent advancements in artificial intelligence (AI), specifically natural language processing (NLP), offer promising solutions for managing polypharmacy. ChatGPT, an AI model developed by OpenAI, has demonstrated high accuracy in medical applications, including the deprescribing process. Recent research presents the first use case of ChatGPT in this context, revealing its potential to align with physician decision-making when managing medication in geriatric patients.

The Impact of AI in Polypharmacy Management

With an ageing population and a decline in regular PCP visits, the need for efficient and accurate medication management is more critical than ever. ChatGPT has shown a propensity to deprescribe medications, particularly in patients without cardiovascular disease history. However, the decision-making process does not solely hinge on the presence of cardiovascular conditions; the severity of impairment in activities of daily living also plays a role.

Limitations and Considerations

Despite its potential, this study acknowledges limitations, including the standardised patient profile used in the vignettes, which may not represent the diversity of the geriatric population. Furthermore, the susceptibility of AI models like ChatGPT to generate incorrect or fabricated information, known as hallucinations, necessitates caution.


The integration of AI, such as ChatGPT, into polypharmacy management could signify a substantial stride forward in improving medication use and reducing adverse drug events among the elderly. Nonetheless, it is imperative to approach this technology with prudence, considering its current limitations and the evolving landscape of medical practice.

Reference url

Recent Posts

Cost and clinical impact of MIS-C

Understanding the Cost and Clinical Impact of Multisystem Inflammatory Syndrome in Children (MIS-C)

🔍 Discovering the Economic Impact of Multisystem Inflammatory Syndrome in Children (MIS-C) 🏥💰

Understanding the cost and clinical impact of MIS-C during COVID-19 is crucial for healthcare providers and policymakers. Learn about treatment costs, patient outcomes, and key statistics related with MIS-C.

🌟#Healthcare #MIS-C #COVID19 #Pediatrics #HealthEconomics #MedicalResearch #HealthcareResearch #MedicalEconomics 📊

Let’s navigate the intersection of healthcare and economics together! 💼 #HealthcareInsights #EconomicAnalysis 🧠


Striking the Balance: Optimising Hepatitis B Treatment Strategies in The Gambia

Hepatitis B continues to pose a significant public health challenge, but the World Health Organization continues to work towards achieving their ambition of eliminating HBV as a public health problem by 2030.

One strategy is the Treat All approach, which sounds promising – however, in low-resource settings implementing promising strategies becomes more complex. This study explores striking the balance between promising strategies and getting people the treatment they need.

Learn more about innovative HBV treatment approaches and their impact on global health. Stay informed and join the conversation! 💡🔬 #HealthcareInnovation #HBVResearch

cost effectiveness multiple sclerosis

Cost-Utility and Cost-Effectiveness of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis

Exploring the Cost-Utility of MS Treatments: A Comprehensive Review 🧠💼 Dive into the latest findings on the cost-effectiveness of Disease-Modifying Drugs for Multiple Sclerosis. Discover key insights and recommendations for optimizing treatment strategies. #MSresearch #HealthcareEconomics #Neurology #HealthTech 📊🔬

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.